• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    4/16/26 5:00:24 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    false 0001979414 0001979414 2026-04-14 2026-04-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported):

    April 14, 2026

     

    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-42567   92-1954864
    (Commission File Number)   (IRS Employer Identification No.)

     

    23975 Park Sorrento, Suite 205 Calabasas, CA   91302
    (Address of Principal Executive Offices)   (Zip Code)

     

    (818) 570-6844

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.0001   NTHI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 7.01. Regulation FD Disclosure.

     

    On April 14, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release announcing that the Chairman and CEO, Amir Heshmatpour, had purchased approximately $300,000 worth of NTHI stock in the last week. The press release also provided additional context regarding the year-over-year change in operating expenses reflected in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)Exhibits

     

    Exhibit No.   Description
    99.1   Press Release, dated April 14, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: April 16, 2026 NeOnc Technologies Holdings, Inc.
         
      By: /s/ Amir Heshmatpour
        Name: Amir Heshmatpour
        Title: Chief Executive Officer, President and Executive Chairman

     

    2

    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    5/19/2026$13.00Buy
    Alliance Global Partners
    5/18/2026$20.00Buy
    Maxim Group
    4/24/2026$15.00Buy
    BTIG Research
    More analyst ratings

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

    DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. Yet one of oncology's greatest challenges remains largely unsolved. Glioblastoma. Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with the difficulty of delivering therapies into the brain, has mad

    6/3/26 9:28:24 AM ET
    $BNTX
    $IBRX
    $KZIA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode

    DENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the

    6/1/26 9:05:00 AM ET
    $LLY
    $NTHI
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Next Great AI Revolution May Be Drug Delivery

    DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet some of the most important long-term applications of AI may ultimately emerge inside healthcare, particularly in the development and delivery of advanced therapeutics. The biotechnology sector is rapidly entering a new era where AI is no longer just helping discover drugs, it is beginning to reshape how therapies are delivered, personalized, monitored, and commercialized. This shift could become most important in diseases involving the brain and central nervous system. That is

    5/29/26 9:05:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on NeOnc Technologies Holdings with a new price target

    Alliance Global Partners initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $13.00

    5/19/26 8:31:51 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on NeOnc Technologies Holdings with a new price target

    Maxim Group initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $20.00

    5/18/26 8:44:12 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on NeOnc Technologies Holdings with a new price target

    BTIG Research initiated coverage of NeOnc Technologies Holdings with a rating of Buy and set a new price target of $15.00

    4/24/26 8:06:10 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $41,592 worth of shares (10,000 units at $4.16), increasing direct ownership by 0.33% to 3,072,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/4/26 2:08:58 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $45,180 worth of shares (10,000 units at $4.52), increasing direct ownership by 0.33% to 3,062,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/28/26 6:00:05 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $2,440 worth of shares (500 units at $4.88), increasing direct ownership by 0.37% to 134,760 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    4/24/26 6:10:07 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    SEC Filings

    View All

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    5/18/26 5:00:15 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by NeOnc Technologies Holdings Inc.

    SCHEDULE 13G - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Subject)

    5/15/26 4:59:25 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

    10-Q - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    5/15/26 4:32:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints David Choi as Chief Accounting Officer

    CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations. "David's extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc," said

    3/13/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

    CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di

    11/4/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Provides Business Update and Reports Q1 2026 Financial Results

    CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company advancing two Phase 2 programs in central nervous system (CNS) cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent operational achievements and upcoming milestones. Amir Heshmatpour, Chief Executive Officer, Executive Chairman, and President, commented: "The first quarter of 2026 marked a transformational period for NeOnc as we advanced both of our lead clinical programs toward important regulatory and value-creation milestones. We successfully comp

    5/18/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

    CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET. NeOnc has formally notified the FDA that the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial has reached Maximum Tolerated Dose (MTD) at Cohort 5 (810 mg, Days 1–5, 28-day cycle) following a second

    3/4/26 8:00:00 AM ET
    $MRK
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

    CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time. During the call, members of the NeOnc management team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated

    2/27/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care